• Brodie MJ. (2010) Antiepileptic drug therapy the story so far. Seizure 19:650655.
  • Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. (2012) A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 61:517522.
  • Eisai Inc. (2013) Data on file. Woodcliff Lake, NJ.
  • European Medicines Agency. (2012) Fycompa summary of product characteristics. London, United Kingdom.
  • Food and Drug Administration. (2012) Fycompa prescribing information, Silver Springs, MD.
  • French JA. (2007) Refractory epilepsy: clinical overview. Epilepsia 48(Suppl. 1):37.
  • French JA, Abou-Khalil BW, Leroy RF, Yacubian EMT, Shin P, Hall S, Mansbach H, Nohria V. (2011) Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76:15551563.
  • French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA. (2012) Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79:589596.
  • French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A. (2013) Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 54:117125.
  • Fuseau E, Templeton D, Hussein Z. (2011) Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr 11(Suppl. 1):abs 1.264.
  • Gazzola DM, Balcer LJ, French JA. (2007) Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 48:13031307.
  • Halász P, Kälviäinen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, Sullivan T. (2009) Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 50:443453.
  • Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y. (2011) Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52:13311340.
  • Hussein Z, Ferry J, Krauss GL, Squillacote D, Laurenza A. (2012) Demographic factors and concomitant antiepileptic drugs have no effect on the pharmacodynamics of perampanel. Neurology 78(Meeting Abstracts 1):abs P06.127.
  • Kramer L, Perucca E, Ben-Menachem E, Kwan P, Shih J, Squillacote D, Yang H, Zhu J, Laurenza A. (2012) Perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: a dose-response analysis from Phase III studies. Neurology 78(Meeting Abstracts 1):abs P06.117.
  • Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. (2012a) Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 125:815.
  • Krauss GL, Kerling F, Villanueva V, Squillacote D, Yang H, Zhu J, Verdian L, Laurenza A. (2012b) Drug resistance and seizure severity of patients in partial-onset seizure registration trials of perampanel compared with recently approved antiepileptic drugs. Epilepsia 53(Suppl. 5):52, abs P176.
  • Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, Yang H, Squillacote D, Edwards HB, Zhu J, Laurenza A. (2012c) Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78:14081415.
  • Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, Yang H, Gee M, Zhu J, Laurenza A. (2013) Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia 54:126134.
  • Rogawski MA. (2011) Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 11:5663.